



THE JOURNAL OF CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Safety of Ketamine Augmentation to Monoamine Oxidase Inhibitors in Treatment-Resistant Depression: A Systematic Literature Review and Case Series

Author(s): Jolien K. E. Veraart, MD; Sanne Y. Smith-Apeldoorn, MD; Mats Kutscher, MSc; Maurice Vischjager, MSc; Annemarie van der Meij, MD; Jeanine Kamphuis, MD, PhD; and Robert A. Schoevers, MD, PhD

DOI Number: <https://doi.org/10.4088/JCP.21m14267>

List of Supplementary Material for the article

1. [Appendix 1](#) Search Syntax
2. [Table 1](#) Quality Assessment According to the JBI Critical Appraisal Tools

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Appendix 1: search syntax

Pubmed: 28-7-2021: 53 hits

("esketamine"[Supplementary Concept] OR esketamine[tiab] OR ketamine[tiab] OR "ketamine"[MeSH Terms] OR ketamin*[tiab])

AND

("mao-i"[Tiab] OR "monoamine oxidase inhibitors"[Pharmacological Action] OR "monoamine oxidase inhibitors"[MeSH Terms] OR "monoamine oxidase inhibitor*"[Tiab] OR "hydrazine"[Supplementary Concept] OR "hydrazin*"[Tiab] OR "hydrazines"[MeSH Terms] OR "isocarboxazid"[MeSH Terms] OR "isocarboxazid*"[Tiab] OR "marplan"[Tiab] OR "nialamide"[MeSH Terms] OR "Niamid*"[Tiab] OR Nialamide[tiab] OR "phenelzine"[MeSH Terms] OR "phenelzine"[Tiab] OR "nardil"[Tiab] OR "nardelzine"[Tiab] OR "Hydracarbazine"[Tiab] OR "tranylcypromine"[MeSH Terms] OR "tranylcypromine"[Tiab] OR "parbate"[Tiab] OR "tranylcypromine"[MeSH Terms] OR "tranylcypromine"[Tiab] OR "jatrosum"[Tiab] OR "moclobemide"[MeSH Terms] OR "moclobemid*"[Tiab] OR "aurorix"[Tiab] OR "manerix"[Tiab] OR "rasagiline"[Supplementary Concept] OR "rasagiline"[Tiab] OR "azilect"[Tiab] OR "selegiline"[MeSH Terms] OR "selegiline*"[Tiab] OR deprenyl*[Tiab] OR "eldepryl"[Tiab] OR "emsam"[Tiab] OR "zelapar"[Tiab] OR "safinamide"[Supplementary Concept] OR "safinamide"[Tiab] OR "xadago"[Tiab])

Embase: 28-7-2021: 125 hits

('esketamine'/exp OR 'ketamin'/exp OR (esketamine OR ketamin*):ab,ti)

AND ('mao i' OR 'monoamine oxidase inhibitor*' OR 'hydrazin*' OR 'isocarboxazid' OR 'marplan' OR 'nialamide' OR 'phenelzine' OR 'nardil' OR nardelzine OR hydracarbazine OR tranylcypromine OR parbate OR jatrosum OR moclobemide OR aurorix OR manerix OR rasagiline OR azilect OR selegiline OR deprenyl OR eldepryl OR emsam OR zelapar OR safinamide OR xadago)

Supplementary Table 1: Quality assessment according to the JBI critical appraisal tools

Legend

Yes: ✓

No: X

Not applicable: –

Checklist for case reports	Were patient's demographic characteristics clearly described?	Was the patient's history clearly described and presented as a timeline?	Was the current clinical condition of the patient on presentation clearly described?	Were diagnostic tests or assessment methods and the results clearly described?	Was the intervention(s) or treatment procedure(s) clearly described?	Was the post-intervention clinical condition clearly described?	Were adverse events (harms) or unanticipated events identified and described?	Does the case report provide takeaway lessons?	Overall appraisal
Doyle et al. 1990 ³⁴	✓	✓	✓	✓	✓	✓	✓	✓	✓
Zigman et al. 2013 ⁴²	✓	✓	✓	✓	✓	✓	✓	✓	✓
Wink et al. 2014 ⁴¹	✓	✓	✓	✓	✓	✓	✓	✓	✓
Dunner et al. 2020 ³⁵	✓	✓	✓	✓	✓	✓	✓	✓	✓

Checklist for case series	Were there clear criteria for inclusion?	Was the condition measured in a standard, reliable way for all participants included?	Were valid methods used for identification of the condition for all participants included?	Did the case series have consecutive inclusion of participants?	Did the case series have complete inclusion of participants?	Was there a clear reporting of the demographic s of the participants in the study?	Was there clear reporting of clinical information of the participants?	Were the outcomes or follow-up results of cases clearly reported?	Was there clear reporting of the presenting site(s)/ clinic(s) demographic information?	Was statistical analysis appropriate?	Overall appraisal
Szymkowicz et al. 2013 ³⁹	✓	✓	✓	X	X	X	✓	✓	✓	–	X
Bartova et al. 2015 ²⁰	✓	X	X	X	X	✓	✓	✓	X	–	X

Kallmunzer et al. 2016 ³⁶	✓	✓	✓	X	X	✓	✓	✓	✓	–	X
Katz et al. 2018 ¹²	X	X	X	X	X	X	✓	✓	X	–	X
Bottemanne et al. 2020 ³³	✓	✓	✓	X	X	X	✓	✓	X	–	X
Lu et al. 2020 ³⁷	✓	✓	✓	X	X	✓	✓	✓	✓	–	X
Wang et al. 2020 ⁴⁰	✓	✓	X	X	X	✓	✓	✓	✓	–	X

Checklist for cohort studies	Were the two groups similar and recruited from the same population?	Were the exposures measured similarly to assign people to both exposed and unexposed groups?	Was the exposure measured in a valid and reliable way?	Were confounding factors identified?	Were strategies to deal with confounding factors stated?	Were the groups/ participants free of the outcome at the start of the study (or at the moment of exposure)?	Were the outcomes measured in a valid and reliable way?	Was the follow up time reported and sufficient to be long enough for outcomes to occur?	Was follow up complete, and if not, were the reasons to loss to follow up described and explored?	Were strategies to address incomplete follow up utilized?	Was appropriate statistical analysis used?	Overall appraisal
Ludwig et al. 2021 ³⁸	✓	✓	✓	✓	✓	✓	✓	✓	✓	–	✓	✓